A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
BSXiaotingPan	B-authors

Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
China	O
MSShenlinLiu	B-authors

A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
10.1097	O
/	O
MD.0000000000019757	O

Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
China	O
MSShenlinLiu	B-authors

A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
10.1097	O
/	O
MD.0000000000019757	O

Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
China	O
MSShenlinLiu	B-authors

A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
BSXiaotingPan	B-authors

Nanjing	O
BSXiaotingPan	B-authors
BS	B-authors
Xiaoting	I-authors
Pan	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
BSHeyunTao	B-authors

Nanjing	O
BSHeyunTao	B-authors
BS	B-authors
Heyun	I-authors
Tao	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
BSMengjunNie	B-authors

Nanjing	O
BSMengjunNie	B-authors
BS	B-authors
Mengjun	I-authors
Nie	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
BSYuanjieLiu	B-authors

Nanjing	O
BSYuanjieLiu	B-authors
BS	B-authors
Yuanjie	I-authors
Liu	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
BSPanHuang	B-authors

Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O

China	O
BSPanHuang	B-authors
BS	B-authors
Pan	I-authors
Huang	I-authors
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O

China	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
,	O
d	O
Changzhou	O
TCM	O
Hospital	O
,	O
e	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
f	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
g	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
China	O
China	O
MSShenlinLiu	B-authors

Nanjing	O
MSShenlinLiu	B-authors
MS	B-authors
Shenlin	I-authors
Liu	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
PhDWeiSun	B-authors

Nanjing	O
PhDWeiSun	B-authors
PhD	O
Wei	B-authors
Sun	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
PhDJianWu	B-authors

Nanjing	O
PhDJianWu	B-authors
PhD	O
Jian	B-authors
Wu	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
PhDTingMa	B-authors
PhDTingMa	B-authors
PhD	O
Ting	B-authors
Ma	I-authors
BSAnweiDai	B-authors
BSAnweiDai	B-authors
BS	O
Anwei	B-authors
Dai	I-authors
PhDJianweiLu	B-authors
PhDJianweiLu	B-authors
PhD	O
Jianwei	B-authors
Lu	I-authors
PhDBaoruiLiu	B-authors
PhDBaoruiLiu	B-authors
PhD	O
Baorui	B-authors
Liu	I-authors
PhDXiZou	B-authors

Nanjing	O
PhDXiZou	B-authors
PhD	O
Xi	B-authors
Zou	I-authors
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
MSQingminSun	B-authors
sunqingminnjmu@163.com	O

Nanjing	O
MSQingminSun	B-authors
MS	O
Qingmin	B-authors
Sun	I-authors
sunqingminnjmu@163.com	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O

Nanjing	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
,	O
b	O
No	O
.	O
1	O
Clinical	O
Medical	O
College	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Nanjing	O
Nanjing	O
NieMLiu	B-authors
NieMLiu	B-authors
Nie	B-authors
M	I-authors
Liu	I-authors
HuangPLiu	B-authors
HuangPLiu	B-authors
Huang	B-authors
P	I-authors
Liu	I-authors
LuJLiu	B-authors
LuJLiu	B-authors
Lu	B-authors
J	I-authors
Liu	I-authors
Ethic	O
Committee	O
of	O
Affiliated	O
Hospital	O

Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
Ethic	O
Committee	O
of	O
Affiliated	O
Hospital	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
The	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Province	O
Hospital	O
of	O
Chinese	O
Medicine	O
Nanjing	O

China	O
Nanjing	O
China	O
A	O
clinical	B-study_type
study	I-study_type
of	O
traditional	O
Chinese	O
medicine	O
prolonging	O
the	O
survival	O
of	O
advanced	O
gastric	O
cancer	O
patients	O
by	O
regulating	O
the	O
immunosuppressive	O
cell	O
population	O
A	O
study	O
protocol	O
for	O
a	O
multicenter	B-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
10.1097	O
/	O
MD.0000000000019757	O
Received	O
:	O
4	O
March	O
2020	O
/	O
Accepted	O
:	O
5	O
March	O
2020	O

Gastric	O
cancer	O
(	O
GC	O
)	O
is	O
an	O
important	O
disease	O
with	O
high	O
morbidity	O
and	O
mortality	O
globally	O
,	O
which	O
ranks	O
the	O
fifth	O
most	O
frequently	O
diagnosed	O
cancer	O
and	O
the	O
third	O
leading	O
cause	O
of	O
cancer	O
death	O
.	O
In	O
2018	O
,	O
over	O
1,000,000	O
new	O
cases	O
were	O
diagnosed	O
with	O
GC	O
and	O
approximately	O
783,000	O
deaths	O
(	O
equating	O
to	O
1	O
in	O
12	O
deaths	O
worldwide	O
)	O
.	O
[	O
1	O
]	O
Most	O
patients	O
(	O
>	O
70	O
%	O
)	O
with	O
GC	O
are	O
diagnosed	O
at	O
the	O
advanced	O
stage	O
,	O
[	O
2	O
]	O
as	O
a	O
consequence	O
,	O
it	O
shows	O
a	O
disappointing	O
result	O
.	O
[	O
3,4	O
]	O
Accumulating	O
evidence	O
shows	O
that	O
only	O
5	O
%	O
of	O
patients	O
with	O
metastatic	O
cancer	O
are	O
still	O
alive	O
5	O
years	O
after	O
diagnosis	O
.	O
[	O
5	O
]	O
In	O
recent	O
years	O
,	O
immune	O
microenvironment	O
has	O
been	O
increasingly	O
valued	O
for	O
its	O
crucial	O
role	O
in	O
the	O
process	O
of	O
GC	O
onset	O
and	O
progression	O
.	O
[	O
6][7][8	O
]	O
Although	O
surgical	O
resection	O
,	O
chemotherapy	O
,	O
radiotherapy	O
,	O
biologic	O
therapeutic	O
agents	O
,	O
and	O
other	O
measures	O
have	O
been	O
used	O
to	O
improve	O
the	O
therapeutic	O
efficacy	O
of	O
GC	O
,	O
[	O
9	O
]	O
the	O
prognosis	O
is	O
still	O
dismal	O
.	O
[	O
10	O
]	O
Thus	O
,	O
it	O
is	O
important	O
to	O
explore	O
new	O
strategies	O
to	O
prolong	O
the	O
survival	O
,	O
improve	O
the	O
quality	O
of	O
life	O
of	O
the	O
advanced	O
GC	O
patients	O
.	O
Fortunately	O
,	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
has	O
its	O
unique	O
advantages	O
in	O
preventing	O
and	O
treating	O
GC	O
[	O
11,12	O
]	O
and	O
it	O
also	O
has	O
an	O
efficacy	O
in	O
improving	O
immune	O
function	O
.	O
[	O
13	O
]	O
The	O
JPYZXZ	O
decoction	O
is	O
a	O
traditional	O
Chinese	O
herbal	O
formulation	O
created	O
by	O
Professor	O
Shenlin	O
Liu	O
,	O
the	O
national	O
famous	O
Chinese	O
Physician	O
.	O
JPYZXZ	O
decoction	O
is	O
composed	O
of	O
12	O
kinds	O
of	O
Chinese	O
herbal	O
medicine	O
,	O
as	O
is	O
shown	O
in	O
Table	O
1	O
.	O
Our	O

The	O
datasets	O
generated	O
during	O
and/or	O
analyzed	O
during	O
the	O
current	O
study	O
are	O
not	O
publicly	O
available	O
,	O
but	O
are	O
available	O
from	O
the	O
corresponding	O
author	O
on	O
reasonable	O
request	O
.	O

previous	O
studies	O
[	O
14	O
]	O
have	O
illustrated	O
that	O
JPYZXZ	O
plays	O
a	O
critical	O
role	O
in	O
improving	O
cancer	O
-	O
related	O
fatigue	O
and	O
prolonging	O
survival	O
in	O
patients	O
with	O
advanced	O
GC	O
and	O
it	O
has	O
been	O
used	O
to	O
treat	O
GC	O
patients	O
in	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
for	O
many	O
years	O
.	O
The	O
aim	O
of	O
our	O
present	O
study	O
is	O
to	O
explore	O
the	O
efficacy	O
and	O
safety	O
of	O
JPYZXZ	B-arm_description
decoction	O
in	O
advanced	O
GC	O
using	O
a	O
multicenter	B-study_type
randomized	I-study_type
controlled	I-study_type
trail	I-study_type
.	O
Meanwhile	O
,	O
the	O
changes	O
of	O
immunosuppressive	O
cell	O
population	O
in	O
peripheral	O
blood	O
of	O
advanced	O
GC	O
patients	O
will	O
be	O
detected	O
to	O
demonstrate	O
the	O
mechanism	O
of	O
JPYZXZ	B-arm_description
decoction	O
.	O

This	O
is	O
a	O
prospective	B-study_type
,	I-study_type
multicenter	I-study_type
,	I-study_type
randomized	I-study_type
controlled	I-study_type
trial	I-study_type
lasting	O
1.5	O
years	O
in	O
6	O
locations	O
,	O
including	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
,	O
Jiangsu	O
Cancer	O
Hospital	O
,	O
Nanjing	O
Drum	O
Tower	O
Hospital	O
,	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Kunshan	O
,	O
Changzhou	O
TCM	O
Hospital	O
and	O
Traditional	O
Chinese	O
Medicine	O
Hospital	O
of	O
Zhangjiagang	O
.	O
A	O
total	O
of	O
210	O
eligibility	O
patients	O
with	O
advanced	O
GC	O
will	O
be	O
enrolled	O
in	O
this	O
trail	O
.	O
All	O
the	O
patients	O
will	O
be	O
randomly	O
assigned	O
into	O
2	O
groups	O
(	O
in	O
a	O
ratio	O
of	O
2:1	O
)	O
:	O
140	O
in	O
the	O
treatment	B-arm_description
group	I-arm_description
(	O
chemotherapy	B-arm_description
plus	O
JPYZXZ	B-arm_description
granules	O
)	O
and	O
70	O
in	O
the	O
control	B-arm_description
group	I-arm_description
(	O
chemotherapy	B-arm_description
alone	O
)	O
.	O
The	O
study	O
protocol	O
has	O
been	O
approved	O
by	O
the	O
Ethic	O
Committee	O
of	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
(	O
Number	O
2019NL-166	O
-	O
02	O
)	O
,	O
and	O
it	O
will	O
be	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
strictly	O
.	O
The	O
study	O
flowchart	O
has	O
been	O
shown	O
in	O
Figure	O
1	O
.	O

After	O
obtaining	O
informed	O
consent	O
from	O
eligible	O
participants	O
,	O
researchers	O
will	O
upload	O
the	O
basic	O
information	O
.	O
Then	O
with	O
the	O
help	O
of	O
the	O
third	O
-	O
party	O
software	O
Medroad	O
Cloud	O
,	O
the	O
random	O
number	O
will	O
be	O
given	O
(	O
https://sci.medroad.cn/	O
)	O
.	O
The	O
participants	O
will	O
be	O
randomly	O
divided	O
into	O
the	O
chemotherapy	B-arm_description
alone	I-arm_description
and	O
chemotherapy	B-arm_description
plus	O
JPYZXZ	B-arm_description
granules	O
groups	O
.	O

A	O
total	O
of	O
210	O
patients	O
with	O
advanced	O
GC	O
will	O
be	O
recruited	O
in	O
this	O
clinical	O
trail	O
.	O
The	O
purpose	O
,	O
benefits	O
and	O
potential	O
risks	O
of	O
this	O
trail	O
and	O
other	O
information	O
will	O
be	O
informed	O
to	O
the	O
patients	O
in	O
detail	O
.	O
All	O
the	O
patients	O
participating	O
in	O
this	O
trail	O
are	O
entirely	O
voluntary	O
,	O
and	O
they	O
can	O
also	O
withdraw	O
at	O
any	O
time	O
during	O
the	O
whole	O
trail	O
without	O
any	O
consequence	O
.	O
Written	O
consent	O
will	O
be	O
obtained	O
from	O
each	O
eligibility	O
patient	O
before	O
them	O
participating	O
in	O
the	O
study	O
.	O
(	O
1	O
)	O
Patients	O
who	O
is	O
unable	O
to	O
swallow	O
oral	O
medications	O
including	O
with	O
digestive	O
tract	O
obstruction	O
and	O
jejunostomy	O
;	O
(	O
2	O
)	O
Patients	O
with	O
symptomatic	O
brain	O
metastasis	O
or	O
mental	O
disorder	O
;	O
(	O
3	O
)	O
Patients	O
with	O
severe	O
cardiovascular	O
disease	O
,	O
chronic	O
liver	O
disease	O
,	O
kidney	O
disease	O
or	O
blood	O
disease	O
;	O
(	O
4	O
)	O
Patients	O
whose	O
laboratory	O
examination	O
before	O
enrollment	O
is	O
abnormal	O
according	O
to	O
the	O
following	O
criteria	O
:	O
Blood	O
routine	O
examination	O
:	O
ANC	O
<	O
2.0	O
Â	O
10	O
9	O
/L	O
,	O
Hb	O
<	O
90	O
g	O
/	O
L	O
,	O
PLT	O
<	O
80	O
Â	O
10	O
9	O
/L	O
,	O
Renal	O
function	O
:	O
Cr	O
>	O
1.5	O
Â	O
upper	O
normal	O
limit	O
(	O
UNL	O
)	O
;	O
2.5.2	O
.	O
The	O
treatment	O
group	O
.	O
Total	O
of	O
140	O
patients	O
in	O
the	O
treatment	O
group	O
will	O
be	O
treated	O
with	O
chemotherapy	B-arm_description
combined	O
with	O
JPYZXZ	B-arm_description
decoction	O
.	O
The	O
chemotherapy	B-arm_description
regimens	O
will	O
be	O
the	O
same	O
as	O
the	O
control	B-arm_description
group	I-arm_description
and	O
the	O
JPYZXZ	B-arm_description
decoction	O
,	O
available	O
in	O
the	O
forms	O
of	O
granules	O
,	O
should	O
be	O
taken	O
at	B-arm_dosage
least	I-arm_dosage
6	B-arm_dosage
months	I-arm_dosage
,	O
per	O
bag	O
twice	B-arm_dosage
daily	I-arm_dosage
,	O
add	O
boiled	O
water	O
in	O
it	O
and	O
mix	O
up	O
it	O
,	O
150	B-arm_dosage
ml	I-arm_dosage
each	I-arm_dosage
time	I-arm_dosage
.	O

The	O
time	O
-	O
points	O
of	O
assessment	O
is	O
listed	O
in	O
Table	O
2	O
.	O
2.6.1	O
.	O
Primary	O
outcomes	O
.	O
The	O
primary	O
outcomes	O
include	O
1year	O
survival	O
rate	O
,	O
progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O
One	O
-	O
year	O
survival	O
rate	O
=	O
(	O
the	O
number	O
of	O
patients	O
still	O
alive	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
/	O
the	O
total	O
number	O
of	O
patients	O
followed	O
up	O
)	O
Â	O
100	O
%	O
.	O
Progression	B-arm_efficacy_metric
-	I-arm_efficacy_metric
free	I-arm_efficacy_metric
survival	I-arm_efficacy_metric
means	O
the	O
time	O
from	O
the	O
start	O
of	O
treatment	O
to	O
recurrence	O
or	O
death	O
due	O
to	O
any	O
causes	O
.	O
OS	O
is	O
the	O
time	O
from	O
the	O
beginning	O
of	O
diagnosis	O
to	O
death	O
for	O
any	O
causes	O
.	O
All	O
of	O
the	O
indicators	O
will	O
be	O
calculated	O
at	O
the	O
end	O
of	O
the	O
trail	O
.	O

2.6.3	O
.	O
Safety	O
evaluation	O
.	O
Blood	O
routine	O
,	O
Liver	O
function	O
,	O
Renal	O
function	O
,	O
and	O
ECG	O
will	O
be	O
monitored	O
regularly	O
to	O
evaluate	O
the	O
safety	O
of	O
JPYZXZ	B-arm_description
decoction	O
.	O

Although	O
adverse	O
effect	O
of	O
JPYZXZ	B-arm_description
has	O
not	O
been	O
observed	O
in	O
preclinical	O
studies	O
,	O
all	O
the	O
researchers	O
should	O
pay	O
close	O
attention	O
to	O
possible	O
adverse	O
reactions	O
,	O
such	O
as	O
vomiting	O
.	O
Any	O
adverse	O
events	O
occurred	O
during	O
the	O
trail	O
should	O
be	O
recorded	O
in	O
"	O
Adverse	O
events	O
form	O
"	O
and	O
the	O
treatment	O
process	O
and	O
results	O
also	O
need	O
to	O
be	O
recorded	O
in	O
detail	O
.	O
When	O
serious	O
adverse	O
events	O
appeared	O
,	O
researchers	O
should	O
terminate	O
the	O
study	O
of	O
the	O
participant	O
of	O
this	O
case	O
and	O
fill	O
out	O
the	O
"	O
serious	O
adverse	O
events	O
form	O
"	O
in	O
truth	O
.	O
Every	O
adverse	O
event	O
needs	O
to	O
be	O
reported	O
to	O
the	O
ethic	O
committee	O
of	O
Affiliated	O
Hospital	O
of	O
Nanjing	O
University	O
of	O
Chinese	O
Medicine	O
.	O

According	O
to	O
our	O
previous	O
study	O
,	O
the	O
average	O
survival	O
time	O
of	O
advanced	O
GC	O
patients	O
treated	O
with	O
chemotherapy	B-arm_description
is	O
257.92	O
±	O
16.56	O
days	O
.	O
Considering	O
that	O
the	O
minimum	O
error	O
clinical	O
accepted	O
is	O
3.5	O
%	O
,	O
a	O
is	O
0.05	O
and	O
test	O
efficiency	O
is	O
80	O
%	O
.	O
The	O
sample	O
size	O
is	O
calculated	O
by	O
the	O
following	O
formula	O
:	O

Considering	O
20	O
%	O
of	O
the	O
drop	O
rate	O
,	O
allocating	O
patients	O
at	O
a	O
ratio	O
of	O
2:1	O
,	O
the	O
total	O
sample	O
size	O
is	O
210	O
(	O
140	O
in	O
chemotherapy	B-arm_description
plus	O
JPYZXZ	B-arm_description
group	O
and	O
70	O
in	O
chemotherapy	B-arm_description
alone	I-arm_description
group	O
)	O
.	O

2.9	O
.	O
Statistical	O
analysis	O
SPSS	O
18.0	O
and	O
other	O
statistics	O
software	O
will	O
be	O
used	O
to	O
analyze	O
the	O
outcomes	O
.	O
Quantitative	O
data	O
will	O
be	O
expressed	O
as	O
the	O
mean	O
±	O
standard	O
deviation	O
,	O
and	O
T	O
test	O
will	O
be	O
used	O
to	O
compare	O
the	O
data	O
between	O
2	O
groups	O
.	O
Qualitative	O
data	O
will	O
be	O
calculated	O
by	O
chisquare	O
test	O
and	O
Fisher	O
test	O
.	O
Quality	O
of	O
life	O
analysis	O
will	O
be	O
performed	O
by	O
repeated	O
measures	O
of	O
variance	O
.	O
The	O
OS	O
and	O
median	O
survival	O
will	O
be	O
analyzed	O
by	O
Kaplan	O
-	O
Meier	O
.	O
All	O
data	O
will	O
be	O
analyzed	O
with	O
a	O
2-sided	O
test	O
and	O
P	O
.05	O
is	O
considered	O
statistically	O
significant	O
.	O

This	O
clinical	O
study	O
started	O
in	O
July	O
2019	O
and	O
is	O
scheduled	O
to	O
end	O
in	O
June	O
2022	O
.	O
So	O
far	O
,	O
we	O
have	O
received	O
the	O
ethical	O
approval	O
and	O
registered	O
at	O
Chinese	O
Clinical	O
Trail	O
Registry	O
(	O
www.chictr.org.cn	O
ChiCTR1900028147	O
)	O
.	O
Patients	O
recruitment	O
is	O
in	O
progress	O
when	O
the	O
manuscript	O
submitted	O
.	O